Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category ... in its cancer pipeline. CDK2 drug shows promise Those include potential first-in-class CDK2 inhibitor INCB123667, which ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first ...

Key Business Updates BRUKINSA ® (zanubrutinib) is an orally available, small molecule inhibitor of BTK designed to deliver ..

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

inhibitor, demonstrates a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile; Investigational New Drug (IND) submission is planned for year-end 2025 and proof-of-concept IgG ...